Business Wire

OH-FORGE-BIOLOGICS

Share
Forge Biologics Receives Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA) for Novel Gene Therapy FBX-101 for the Treatment of Patients with Krabbe Disease

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that the European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge’s lead adeno-associated virus (AAV) drug candidate and novel gene therapy for treating patients with Krabbe disease.

PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up their development and usher them to reach patients faster. The goal is to help patients benefit as early as possible from innovative new therapies that have demonstrated the potential to significantly address and treat patients that have an unmet medical need.

“We are grateful to the EMA for recognizing FBX-101 as a potentially transformative medicine for patients living with this life-threatening and devastating disease,” said Christopher Shilling, Senior Vice President of Regulatory Affairs and Quality at Forge. “Through the enhanced interactions with the EMA granted by the PRIME designation, we will advance and expedite the development of FBX-101 as the leading worldwide gene therapy for patients with Krabbe disease.”

The designation follows positive safety and efficacy data from the ongoing Phase 1/2 RESKUE trial. This positive clinical data was presented by Maria Escolar, M.D., Forge’s Chief Medical Officer at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium in August 2022, and updated in October at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT). The results demonstrated that systemically delivered FBX-101 administered after hematopoetic stem cell transplant (HSCT) is safe and well-tolerated in Krabbe patients. Patients in the low dose cohort demonstrated restoration of GALC enzyme activity, reduced psychosine, showed encouraging signs of normal myelination of brain white matter, and improved motor development as compared to untreated Krabbe patients or patients treated with HSCT alone.

Clinical data support preclinical observations that this gene therapy approach after HSCT infusion may lessen many of the immune challenges previously observed with systemic AAV gene delivery and may create a safer environment for gene replacement. Findings also support this novel approach for extending the delivery of gene replacement strategies to target metabolic diseases amenable to HSCT.

About Krabbe Disease

Krabbe disease is a rare neurodegenerative disease affecting about 1-2.5 in 100,000 people in the U.S. Krabbe disease is caused by autosomal recessive mutations in the galactocerebrosidase (GALC) gene, an enzyme responsible for the breakdown of certain types of sphingolipids, such as psychosine, associated with myelination of the nervous system. Without functional GALC, psychosine accumulates to toxic levels in cells, specifically in cells insulating the nerves in the brain and peripheral nervous system, causing rapid demyelination. Krabbe disease initially manifests as irritability, developmental delay, and progressive muscle weakness; symptoms rapidly advance to difficulty swallowing, breathing, worsening developmental delay, and vision and hearing loss. Infantile Krabbe disease (0 –12 months of age at onset) usually leads to death in untreated patients by 2 years of age. Late Infantile patients (12-36 months of age at onset) usually die by the age of six. The current standard of care, hematopoietic stem cell transplantation (HSCT), has been shown to stabilize cognitive decline and significantly improve long-term neurological outcomes when performed prior to symptom onset. However, HSCT does not correct the peripheral neuropathy that is progressive as the patient grows, leading to loss of gross motor skills and eventually death. Early diagnosis is key for treating Krabbe patients before significant neurological damage has occurred. Currently, 10 states in the USA are conducting newborn screening for Krabbe disease. Infants who screen positive, meaning insufficient GALC activity is detected, undergo psychosine and mutation analysis to confirm the diagnosis and predict disease onset.

About FBX-101

FBX-101 was developed to treat children with Krabbe disease. FBX-101 is an adeno-associated viral serotype rh10 (AAVrh10) gene therapy that is delivered intravenously after HSCT infusion. The vector delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system. FBX-101 has been shown to functionally correct the central and peripheral neuropathy associated with Krabbe, improve gross motor outcomes, and significantly prolong lifespan in animal models. This approach has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies and extend the duration of gene transfer.

About the RESKUE Trial

RESKUE a Phase 1/2 clinical trial to investigate the safety and efficacy of FBX-101 in patients with Infantile Krabbe disease. It is a nonblinded, non-randomized dose escalation study of intravenous AAVrh10 after HSCT infusion, in which subjects receive standard of care hematopoietic cell transplantation for Krabbe Disease, followed by a single infusion of an adeno-associated virus gene therapy product. Extensive natural history subjects will be used to compare as control group. More information on the RESKUE trial can be found online at https://www.clinicaltrials.gov/ct2/show/NCT04693598.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005486/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ThinkPalm and RAD Join Forces to Deliver a Smart Business IoT Solution, Offering CSPs a Competitive Edge17.9.2025 09:00:00 CEST | Press release

ThinkPalm and RAD have partnered to integrate NetvirE, ThinkPalm’s advanced IIoT platform, and RAD’s Smart Business IoT solution to enable smarter industrial operations. This collaboration gives Communication Service Providers (CSPs) a competitive edge in digital transformation, remote asset management, and IoT services. 360°, End-to-End IoT Offering The Smart Business IoT solution combines advanced IoT gateways, smart sensors, and intelligent dashboards into one integrated system. It delivers real-time, historical, and AI-driven insights for remote monitoring, predictive maintenance, and activity detection, enabling CSPs to move beyond SIM-based plans and offer high-value, integrated solutions for smarter asset decisions without requiring IT expertise. Expanding CSP Horizons in the UK and Europe For CSPs in competitive markets like the UK and Europe, ThinkPalm’s expertise combined with RAD's industry leadership offers an unparalleled advantage. Together, they deliver secure, tailored

EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 08:57:00 CEST | Press release

Almirall’s scientific presence at the 34th EADV congress reflects its broad portfolio of dermatological treatments and patient-centric approach - featuring 44 abstracts, two expert-led symposia on atopic dermatitis and psoriasis, and an interactive booth. Lebrikizumab’s effectiveness in the treatment of moderate-to-severe atopic dermatitis is demonstrated by new real-world evidence, and long-term efficacy and patient well-being data. New real-world data demonstrate tildrakizumab’s effectiveness in the treatment of psoriasis in high-impact areas of the body and across multiple patient groups - particularly elderly patients and those with high disease burden. Almirall’s pipeline progress includes new initial phase 1 data on a developmental treatment for Hidradenitis Suppurativa (HS), LAD191 a monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL-1RAP) shows preliminary signs of clinical symptom improvements, and a favourable safety and tolerability profile. Almir

SES delivered unprecedented MEO satellite connectivity for French Navy’s Clemenceau 25 mission17.9.2025 08:50:00 CEST | Press release

During international operations, SES’s high-throughput low-latency Medium Earth Orbit (MEO) managed satcom service provided connectivity to flagship aircraft carrier Charles de Gaulle of the French Carrier Strike Group (GAN) SES announced today that the French Navy’s aircraft carrier Charles de Gaulle leveraged its secure and reliable O3b mPOWER satcom service – Managed Naval mPOWERED – during the Clemenceau 25 mission. This high-throughput, low-latency Medium Earth Orbit (MEO) connectivity solution supported all of the aircraft carrier’s operations, while facilitating collaboration with mission partners. During the five-month deployment, the French Carrier Strike Group (GAN) covered 40,000 nautical miles and conducted various exercises and joint activities with around twenty allied nations. The connectivity provided by SES ensured optimal performance and uninterrupted operational availability for the aircraft carrier’s mission-critical applications. Thanks to the global reach, reliabi

Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 08:00:00 CEST | Press release

Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints

Overture Life Launches European Preorder Waitlist for DaVitri, the World’s First Microfluidics-Based Automated Vitrification Platform17.9.2025 07:00:00 CEST | Press release

Ahead of receipt of anticipated CE Mark, European customers can begin requesting DaVitri to expand patient access to high-quality IVF Overture Life, the innovator modernizing IVF to optimize reproductive freedom, today announced the launch of its European preorder waitlist for DaVitri, the world’s first automated vitrification platform. The waitlist ensures in vitro fertilization (IVF) facilities will be among the first in Europe to harness DaVitri to reduce manual workloads for their embryologists while eliminating operator variability, thereby providing patients with faster, more consistent procedures. As infertility rates spike worldwide, interest in egg freezing continues to rise while the infrastructure to support it lags behind. Egg freezing requires vitrification, typically a time-intensive, manual process vulnerable to human error that can only be performed by extensively trained embryologists. This has resulted in variability in egg and embryo survival rates that directly impa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye